Novartis AG ADR (NVS)vsPhibro Animal Health Corporation (PAHC)
NVS
Novartis AG ADR
$162.55
+0.38%
HEALTHCARE · Cap: $303.67B
PAHC
Phibro Animal Health Corporation
$32.96
-6.89%
HEALTHCARE · Cap: $1.58B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 3679% more annual revenue ($57.36B vs $1.52B). NVS leads profitability with a 17.5% profit margin vs 6.6%. PAHC appears more attractively valued with a PEG of 1.68. PAHC earns a higher WallStSmart Score of 60/100 (C+).
NVS
Hold48
out of 100
Grade: D+
PAHC
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-68.3%
Fair Value
$95.56
Current Price
$162.55
$66.99 premium
Margin of Safety
-9.1%
Fair Value
$47.21
Current Price
$32.96
$14.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.3%
Generating 5.6B in free cash flow
Every $100 of equity generates 26 in profit
Attractively priced relative to earnings
Earnings expanding 24.6% YoY
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.2x book value
4.7% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
4.8% revenue growth
Smaller company, higher risk/reward
6.6% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bull Case : PAHC
The strongest argument for PAHC centers on Return on Equity, P/E Ratio, EPS Growth.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : PAHC
The primary concerns for PAHC are PEG Ratio, Revenue Growth, Market Cap. Debt-to-equity of 2.05 is elevated, increasing financial risk.
Key Dynamics to Monitor
NVS carries more volatility with a beta of 0.47 — expect wider price swings.
PAHC is growing revenue faster at 4.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
PAHC scores higher overall (60/100 vs 48/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Phibro Animal Health Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Phibro Animal Health Corporation develops, manufactures and supplies a range of mineral nutrition and animal health products for livestock primarily in the United States. The company is headquartered in Teaneck, New Jersey.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?